FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3031689467> ?p ?o ?g. }

• W3031689467 endingPage "9035" @default.
• W3031689467 startingPage "9035" @default.
• W3031689467 abstract "9035 Background: Stereotactic Ablative Radiotherapy (SABR) provides > 95% local control and has become standard care of medically inoperable stage I NSCLC. However, cumulatively about 40% of patients develop recurrence in the regional lymph nodes, distant organs, or secondary lung cancer. Combined immunotherapy and SABR (I-SABR) may reduce these recurrences by stimulating stronger cancer specific immune response. Methods: This is an ongoing phase II randomized study (SABR vs. I-SABR) to evaluate the efficacy and toxicity of I-SABR in medically inoperable, early stage (T1-T3: < 7 cm, including multi-primary tumors), isolated recurrence NSCLC without lymph node or distant metastasis. The primary objective is event-free survival (any recurrence and/or death). Secondary objectives include rates of ≥Grade 2 toxicity. 4-D CT image guided SABR (50 Gy in 4 fractions or 70 Gy in 10 fractions) was delivered to all patients. Patients randomized to I-SABR received additional concurrent Nivolumab (240 mg, every two weeks for total of 7 doses or 480 mg every four weeks for total of 4 doses). 140 patients are anticipated to enroll. We report here interim analysis of toxicity. Results: 92 patients (median age: 72, range: 57 to 90) were enrolled and randomized (47 to SABR; 45 to I-SABR). With median follow up of 14.5 months (range 2 to 28 months), there were no treatment-related grade 4/5 adverse events. For the I-SABR arm, there was one case of possible related grade 3 dyspnea, skin rash and 2 cases of probable grade 3 fatigue. There were possible/probable treatment related 2 cases of grade 2 pneumonitis, fatigue, pruritus and 1 case of grade 2 hyperthyroidism and arthralgia. No patients discontinued treatment due to adverse effects. For the SABR arm, there were possible treatment related 1 case of grade 2 fatigue and pneumonitis. All symptoms resolved with or without treatment. Conclusions: Combined Nivolumab immunotherapy and SABR (I-SABR) appear to be well-tolerated in this fragile patient population with no grade 4/5 toxicity. All toxicities were tolerable and resolved. The major barrier for patient enrollment and/or randomization is patient’s perception of potential toxicities and additional clinic visits. Continued enrollment and additional follow up are needed to validate these findings. Clinical trial information: NCT03110978." @default.
• W3031689467 created "2020-06-05" @default.
• W3031689467 creator A5004505157 @default.
• W3031689467 creator A5006353545 @default.
• W3031689467 creator A5008781374 @default.
• W3031689467 creator A5012745900 @default.
• W3031689467 creator A5016730067 @default.
• W3031689467 creator A5023910969 @default.
• W3031689467 creator A5040095241 @default.
• W3031689467 creator A5048380048 @default.
• W3031689467 creator A5059550832 @default.
• W3031689467 creator A5078248328 @default.
• W3031689467 creator A5085763839 @default.
• W3031689467 creator A5086483620 @default.
• W3031689467 creator A5090494627 @default.
• W3031689467 date "2020-05-20" @default.
• W3031689467 modified "2023-10-13" @default.
• W3031689467 title "I-SABR phase II randomized study of nivolumab immunotherapy and stereotactic ablative radiotherapy in early stage NSCLC: Interim analysis adverse effects." @default.
• W3031689467 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.9035" @default.
• W3031689467 hasPublicationYear "2020" @default.
• W3031689467 type Work @default.
• W3031689467 sameAs 3031689467 @default.
• W3031689467 citedByCount "5" @default.
• W3031689467 countsByYear W30316894672020 @default.
• W3031689467 countsByYear W30316894672021 @default.
• W3031689467 countsByYear W30316894672022 @default.
• W3031689467 crossrefType "journal-article" @default.
• W3031689467 hasAuthorship W3031689467A5004505157 @default.
• W3031689467 hasAuthorship W3031689467A5006353545 @default.
• W3031689467 hasAuthorship W3031689467A5008781374 @default.
• W3031689467 hasAuthorship W3031689467A5012745900 @default.
• W3031689467 hasAuthorship W3031689467A5016730067 @default.
• W3031689467 hasAuthorship W3031689467A5023910969 @default.
• W3031689467 hasAuthorship W3031689467A5040095241 @default.
• W3031689467 hasAuthorship W3031689467A5048380048 @default.
• W3031689467 hasAuthorship W3031689467A5059550832 @default.
• W3031689467 hasAuthorship W3031689467A5078248328 @default.
• W3031689467 hasAuthorship W3031689467A5085763839 @default.
• W3031689467 hasAuthorship W3031689467A5086483620 @default.
• W3031689467 hasAuthorship W3031689467A5090494627 @default.
• W3031689467 hasConcept C106159729 @default.
• W3031689467 hasConcept C121608353 @default.
• W3031689467 hasConcept C126322002 @default.
• W3031689467 hasConcept C141071460 @default.
• W3031689467 hasConcept C143998085 @default.
• W3031689467 hasConcept C162324750 @default.
• W3031689467 hasConcept C168563851 @default.
• W3031689467 hasConcept C187625094 @default.
• W3031689467 hasConcept C197934379 @default.
• W3031689467 hasConcept C2777701055 @default.
• W3031689467 hasConcept C2780030458 @default.
• W3031689467 hasConcept C509974204 @default.
• W3031689467 hasConcept C61943457 @default.
• W3031689467 hasConcept C71924100 @default.
• W3031689467 hasConcept C85393063 @default.
• W3031689467 hasConcept C91602232 @default.
• W3031689467 hasConceptScore W3031689467C106159729 @default.
• W3031689467 hasConceptScore W3031689467C121608353 @default.
• W3031689467 hasConceptScore W3031689467C126322002 @default.
• W3031689467 hasConceptScore W3031689467C141071460 @default.
• W3031689467 hasConceptScore W3031689467C143998085 @default.
• W3031689467 hasConceptScore W3031689467C162324750 @default.
• W3031689467 hasConceptScore W3031689467C168563851 @default.
• W3031689467 hasConceptScore W3031689467C187625094 @default.
• W3031689467 hasConceptScore W3031689467C197934379 @default.
• W3031689467 hasConceptScore W3031689467C2777701055 @default.
• W3031689467 hasConceptScore W3031689467C2780030458 @default.
• W3031689467 hasConceptScore W3031689467C509974204 @default.
• W3031689467 hasConceptScore W3031689467C61943457 @default.
• W3031689467 hasConceptScore W3031689467C71924100 @default.
• W3031689467 hasConceptScore W3031689467C85393063 @default.
• W3031689467 hasConceptScore W3031689467C91602232 @default.
• W3031689467 hasIssue "15_suppl" @default.
• W3031689467 hasLocation W30316894671 @default.
• W3031689467 hasOpenAccess W3031689467 @default.
• W3031689467 hasPrimaryLocation W30316894671 @default.
• W3031689467 hasRelatedWork W2163275813 @default.
• W3031689467 hasRelatedWork W2181841765 @default.
• W3031689467 hasRelatedWork W2301488980 @default.
• W3031689467 hasRelatedWork W2518309888 @default.
• W3031689467 hasRelatedWork W2534538480 @default.
• W3031689467 hasRelatedWork W2760957248 @default.
• W3031689467 hasRelatedWork W3202525722 @default.
• W3031689467 hasRelatedWork W3203711520 @default.
• W3031689467 hasRelatedWork W4283812751 @default.
• W3031689467 hasRelatedWork W4302292908 @default.
• W3031689467 hasVolume "38" @default.
• W3031689467 isParatext "false" @default.
• W3031689467 isRetracted "false" @default.
• W3031689467 magId "3031689467" @default.
• W3031689467 workType "article" @default.